Commonwealth Laboratories has entered into an agreement with Quest Diagnostics.
Here are five key notes:
1. The agreement will expand the availability of IBSchek.
2. Clinicians will be able to order blood draws on patients for testing through Quest's approximately 2,200 patient service centers and 4,000 phlebotomists in the United States.
3. Specimens will then be forwarded to Commonwealth's clinical laboratory in Salem, Mass., for testing.
4. The IBSchek is a new laboratory-developed blood test designed to help physicians diagnose irritable bowel syndrome.
5. Commonwealth launched IBSchek in May 2015.